AILINCOM 
SalusRecent studies have shown that oral GLP-1 medications not only reduce appetite but also decrease the pleasure derived from eating by affecting the brain's reward system. This discovery opens up new possibilities for managing eating behavior.
SalusA new study has shown that the effectiveness of GLP-1 therapy for type 2 diabetes depends on the patient's eating behavior. The greatest success is seen in those who tend to overeat in response to external cues rather than emotions.
SalusA new study has shown that tirzepatide can temporarily reduce compulsive food cravings in patients with obesity by suppressing activity in the brain's reward center. However, the effect of the drug was short-lived, highlighting the need to find more sustainable treatments for overeating and eating disorders.
SalusFor the first time, the WHO has issued guidelines on the use of GLP-1 drugs for treating obesity, highlighting their effectiveness but also emphasizing their high cost and the need for a comprehensive approach. Experts caution about the lack of long-term studies and stress the importance of prevention.
SalusA new study has found that young people with obesity already show brain damage biomarkers typically associated with aging, especially when choline levels are low. This may indicate an early risk of cognitive impairment and highlights the importance of proper nutrition for brain health.
SalusA new study has shown that people with greater muscle mass and less visceral fat tend to have a biologically younger brain. This highlights the importance of maintaining muscle and reducing hidden fat for brain health.